https://doi.org/10.31288/oftalmolzh20135913

The level of of activated lymphocytes molecular markers expression in peripheral blood in patients with uveal melanoma in varying efficiency preserving therapy

Velichko L

SI «The Filatov Institute of Eye Diseases and Tissue Therapy NAMS of Ukraine», Odessa

Introduction. Changing the level of receptor expression on the cell surface reflects processes occurring in the body. Over the last decade, there are many facts that indicate the role of immune mechanisms in the development and progression of cancer.

Purpose — to study the level of activated lymphocytes molecular markers expression in patients with uveal melanoma with different organ-preserving therapy. 

Material and methods. In 150 patients with uveal melanoma the level of expression of molecular markers of lymphocyte activation SD7 + SD25 + SD38 + SD45 + SD54 + SD95 + SD150 + were studied. Patients were divided into two groups: I group — 116 patients with uveal melanoma regression after photocoagulation and P- therapy; II group — 34 patients with progressive tumor growth and subsequent removal of the eye. Blood sampling in patients with uveal melanoma was conducted prior to treatment.

Results. Studying the level expression of molecular markers of activated lymphocytes in patients with progressive tumor growth and regression of uveal melanoma showed that patients with tumor resorption markers of lymphocyte activation level was higher than in patients with progressive tumor growth . It is proved that the absolute level of expression SD54 + significantly higher in patients with melanoma regression (278.3 (183.9)) cells / ml compared to patients with subsequent tumor growth (190.0 (129.5)) cells / ml, p = 0.03. SD95 + expression level is higher in patients with melanoma regression (323.2 (206.3)) cells /ml compared to patients with subsequent tumor growth (218.6 (133.8)) cells / ml, p = 0.02. 

Conclusion. It is established that the level of expression of lymphocyte activation markers investigated in patients with uveal melanoma tumor regression after organ-preserving treatment is higher than in patients with progressive tumor growth. Molecular markers of lymphocyte activation SD54 + SD95 + can be used to predict the performance of organ preserving treatment (regression of uveal melanoma, further progressive tumor growth).

Key words: uveal melanoma, molecular markers of activated lymphocytes predict treatment outcome

References

1.Brovkina AF. Enucleation in the treatment of melanoma. Vestn Oftalmol. 1984; 3: 35-6.

2.Velichko LN. Degtyarenko TV, Maletskii AP. Change of phagocytic activity of monocytes / macrophages in patients with uveal melanoma while complex therapy including laferon. Oftalmol Zh. 1997; 5: 348- 52.

3.Velichko LN, Maletskii AP, Vit VV. State of cancer resis-tance of patients with uveal melanoma in organ-saving treatment. Oftalmol Zh. 1998; 1: 131-40.

4.Velichko LN, Vit VV, Maletskii AP. Transformation of monocytes into macrophages in the autologous serum of patients with uveal tract melanoma in the eyes during organ-saving treatment. Oftalmol Zh. 1997; 1: 39-41.

5.Vit VV. Prognostic value of morphological characters of immune response in various uveal melanoma cell type. Arkh Patol. 1983; 7: 25- 35.

6.Vit VV. Change of uveal melanoma during photocoagula-tion. Arkh Patol. 1985; 47(7): 23- 9.

7.Vit VV. Pathological anatomy and medical pathomorphosis of pigmentosa tumors of uveal tract of the human eye: au-thor's abstract... Doc. Of Med. Sc.: spec. 14.03.02. Patho-logic anatomy. Odessa; 1987. 30 p.

8.Vit VV. Photosensibilization of uveal Melanoma cells with ionizing radiation. Oftalmol Zh. 1990;8: 484- 9.

9.Vit VV. Tumor pathology of vision organ. Odessa: Astro-print; 2009; 1. 610 p.

10.Volkov VV. On indications to enucleating during the treat-ment of patients with intraocular melanoma. Vestn Oftalmol. 1983; 2: 3-6.

11.Gluzman DF, Sklyarenko LM, Nadgornaya VA, Krya-chok IA. Diagnostic immunocytochemistry of tumors. Kiev: Morion; 2003.

12.Yaknitskaya LK, Krasilnikova VL, Kovalenko yud. Enucleation in modern ophthalmology. Zdravookhraneniye Belorusse 2001; 12: 37-8.

13.Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011; 33(4): 335- 40.
Crossref

14.Blom DJ, Luyten GP, Mooy C et al. Human leukocyte anti-gen class I expression. Marker of poor prognosis in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 1997; 38(9): 1865- 72.

14.Blom D. J. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma / D. J. Blom, G. P. Luyten, C. Mooy et al. // Invest. Ophthalmol. Vis. Sci. — 1997. — V. 38. — № 9. — P. 1865- 1872.

15.De W?ard-Siebinga I. HLA expression and tumor-infil-trating immune cells in uveal melanoma / I. de Waard-Siebinga, C. G. Hilders, B. E. Hansen // Graefes Arch. Clin. Exp. Ophthalmol. —  1996. — V. 234. — № 1. — P. 34-42.
Crossref

16.Fridman W. H. Prognostic and predictive impact of intra and peritumoral immune infiltrates / W. H. Fridman, J. Galon, F. Pages et al. // Cancer Res. — 2011. — V. 71. — № 17. — P. 5601- 5605.
Crossref

17.Makitie T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma / T. Makitie, P. Summanen, A. Tarkkanen, T. Kivela // Invest. Ophthalmol. Vis. Sci. — 2001. — V. 42. — № 7. — P. 1414-1421.

18.Singh A. D. Prognostic factors in uveal melanoma / A. D. Singh, C. L. Shields, J. A. Shields // Melanoma Res. — 2001. — V. 11. — P. 255- 263.
Crossref

19.Vetter C. S. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma / C. S. Vetter, W. Lieb, E. B. Brocker, J. C. Becker // Br. J. Cancer. — 2004. — V. 91. — № 8. — P. 1495- 1499.
Crossref

15.De Wiard-Siebinga I, Hilders CG, Hansen BE. HLA ex-pression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch. Clin. Exp. Ophthalmol. 1996; 234(1); 34-42.
Crossref

16.Fridman WH , Galon J, Pages F et al. Prognostic and pre-dictive impact of intra and peritumoral immune infiltrates. Cancer Res. 2011; 71(17): 5601- 5.
Crossref

17.Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2001; 42(7): 1414-21.

18.Singh A. D, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001; 11: 255- 63.
Crossref

19.Vetter CS, Lieb W, Brocker EB, Becker JC. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br. J. Cancer. 2004; 91(8): 1495- 9.
Crossref